Skip to main content
BICYCLE THERAPEUTICS PLC logo

BICYCLE THERAPEUTICS PLC — Investor Relations & Filings

Ticker · BCYC ISIN · US0887861088 LEI · 213800XKUI6R7GKC3E43 US Manufacturing
Open in API
Filings indexed 598 across all filing types
Latest filing 2020-11-05 Regulatory Filings
Country GB United Kingdom
Listing US BCYC

About BICYCLE THERAPEUTICS PLC

https://www.bicycletherapeutics.com/

Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing a novel class of medicines known as Bicycle® molecules. These are fully synthetic bicyclic peptides engineered to combine the targeting specificity and pharmacological properties of large molecule biologics with the rapid and deep tissue penetration of small molecules. The company's proprietary platform creates precision-guided therapeutics to address diseases underserved by existing treatments. The primary focus of its development pipeline is in oncology, with a portfolio of candidates designed to target solid tumors. Beyond oncology, Bicycle Therapeutics leverages its technology through collaborations to explore applications in other therapeutic areas, including anti-infectives, cardiovascular diseases, and central nervous system disorders.

Recent filings

Filing Released Lang Actions
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated November 5, 2020, reporting the issuance of a press release announcing financial results for the fiscal quarter ended September 30, 2020. The text explicitly states that the press release is being furnished as an exhibit and that the information is not deemed "filed" for certain regulatory purposes. The document length is 3930 characters, which is relatively short and primarily serves as an announcement of the earnings release rather than containing the earnings data itself. According to the "MENU VS MEAL" rule, such a document is an announcement of a report rather than the report itself. Therefore, this filing should be classified as an Earnings Release (ER) since it announces quarterly financial results, but given the short length and nature, it is more appropriate to classify it as a Regulatory Filing (RNS) because it is a Form 8-K furnishing a press release rather than the press release text itself. However, since the document includes the press release as an exhibit (Exhibit 99.1), and the main content is the Form 8-K, the best classification is Regulatory Filings (RNS).
2020-11-05 English
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated October 2, 2020, by Bicycle Therapeutics plc. It reports on a Controlled Equity Offering Sales Agreement and a prospectus supplement registering an additional offering of American Depositary Shares up to $75 million. The content focuses on financing activities, specifically the terms and conditions of the equity offering and the sales agreement with sales agents. There are no financial statements or detailed financial results presented, nor is this an annual or quarterly report. The document is not a report publication announcement or a certification. Given the focus on fundraising and capital structure changes, this fits the Capital/Financing Update category (CAP). The document length (6461 characters) supports it being a substantive filing rather than a brief announcement. Therefore, the classification is CAP with high confidence.
2020-10-02 English
424B5
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) related to a shelf registration statement on Form S-3. It details an offering of American Depositary Shares (ADSs) up to $75 million, including terms of the offering, sales agents, risk factors, and use of proceeds. The document is a detailed offering prospectus supplement and base prospectus, which are typical for capital raising activities. It is not a financial report, earnings release, or management discussion, nor is it a regulatory filing or announcement of a report. The content clearly relates to a capital/financing update describing a securities offering. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length (15,000 characters) and detailed content support this classification with high confidence.
2020-10-02 English
FORM 8-K
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated September 30, 2020, reporting the entry into a material definitive agreement—a loan and security agreement with Hercules Capital, Inc. It details the terms of the loan, interest rates, covenants, and other financing-related information. The document is not a full financial report but an announcement of a financing event. The presence of detailed financing terms and the nature of the filing indicate it is a Capital/Financing Update. The document length (7,958 characters) supports it being a substantive filing rather than a brief announcement. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2020-10-01 English
OWNERSHIP DOCUMENT
Director's Dealing
2020-09-18 English
SCHEDULE 13G
Major Shareholding Notification
2020-09-15 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.